The CDC and FDA Are in Talks to Streamline the Authorization of an Omicron Vaccine
The director of the Centers for Disease Control and Prevention (CDC) confirmed on Sunday that the Food and Drug Administration (FDA) was in discussions to streamline the authorization of an omicron-specific vaccine.
“You know, one of the things about a booster — about a variant-specific booster — I know Moderna, Pfizer, Johnson and Johnson say they can all do this fairly quickly, within three months. But then you have FDA approval. Is there any world where you can see that moving much faster given we’ve already been through this?” “This Week” co-anchor Martha Raddatz asked CDC Director Rochelle Walensky on ABC.
“Yeah, you know, much of that I would have to defer to the FDA, but they’re already in conversations about streamlining the authorization of this, of an omicron-specific vaccine, partially because much of the vaccine is actually exactly the same, and, really, it would just be that mRNA code that would have to change,” Walensky answered.
